| Investor | Kingdon Capital Management, L.l.c. |
13D/G Filings
This page shows a list of all the recent 13D/G filings made by Kingdon Capital Management, L.l.c. . Schedule 13D is commonly referred to as a “beneficial ownership report.” The term "beneficial owner" is defined under SEC rules. It includes any person who directly or indirectly shares voting power or investment power (the power to sell the security).
When a person or group of persons acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities, they are required to file a Schedule 13D within ten days after the purchase. Click the link icon to see the full transaction history.
| Date | Form | Target | Prev Shares |
Current Shares |
Change (Percent) |
Ownership (Percent) |
Change (Percent) |
|
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | 13G/A | NVNO / enVVeno Medical Corporation | 1,359,261 | 36,166 | ||||
| 2026-02-17 | 13G/A | SCYX / SCYNEXIS, Inc. | 2,237,048 | 0 | ||||
| 2025-11-12 | 13G/A | SCYX / SCYNEXIS, Inc. | 2,237,048 | 2,237,048 | ||||
| 2025-11-12 | 13G/A | JSPR / Jasper Therapeutics, Inc. | 765,000 | 1,324,845 | ||||
| 2025-09-09 | 13G | NVNO / enVVeno Medical Corporation | 1,359,261 | |||||
| 2025-07-11 | 13G | JSPR / Jasper Therapeutics, Inc. | 765,000 | |||||
| 2025-04-14 | 13G | OPTN / OptiNose, Inc. | 520,485 | |||||
| 2024-11-13 | 13G/A | CRIS / Curis, Inc. | 345,730 | 90,000 | ||||
| 2024-04-15 | 13G | CRIS / Curis, Inc. | 345,730 | |||||
| 2024-02-06 | 13G/A | AMNL / Applied Minerals, Inc. | 30,906,049 | 21,265,377 | ||||
| 2024-02-06 | 13G/A | PRAX / Praxis Precision Medicines, Inc. | 346,665 | |||||
| 2023-11-29 | 13G/A | SCYX / SCYNEXIS, Inc. | 1,697,048 | 2,237,048 | ||||
| 2023-04-13 | 13G | SCYX / SCYNEXIS, Inc. | 1,697,048 | |||||
| 2023-02-06 | 13G/A | AMNL / Applied Minerals, Inc. | 20,969,195 | 30,906,049 | ||||
| 2023-01-25 | 13G | PRAX / Praxis Precision Medicines, Inc. | 2,855,989 | |||||
| 2022-02-10 | 13G/A | AMNL / Applied Minerals, Inc. | 20,565,027 | 20,969,195 | ||||
| 2021-01-11 | 13G | AMNL / Applied Minerals, Inc. | 20,565,027 | 20,565,027 | ||||
| 2021-01-11 | 13G | AMNL / Applied Minerals, Inc. | 19,373,489 | 20,565,027 | ||||
| 2020-02-10 | 13G/A | JAGX / Jaguar Health, Inc. | 1,993,015 | 270 | ||||
| 2020-02-10 | 13G/A | GTYH / GTY Technology Holdings Inc | 1,600,000 | 1,598,212 | ||||
| 2020-02-10 | 13G/A | SESN / Sesen Bio Inc. | 5,239,557 | 4,040,835 | ||||
| 2019-02-08 | 13G/A | JAGX / Jaguar Health, Inc. | 5,462,248 | 1,993,015 | ||||
| 2019-02-04 | 13G | GTYH / GTY Technology Holdings Inc | 1,600,000 | |||||
| 2019-02-04 | 13G/A | SESN / Sesen Bio Inc. | 5,239,557 | |||||
| 2018-06-11 | 13D | AMNL / Applied Minerals, Inc. | 18,846,905 | 19,373,489 | ||||
| 2018-04-04 | 13G | SESN / Sesen Bio Inc. | 2,213,980 | |||||
| 2018-04-02 | 13G/A | XAIR / Beyond Air, Inc. | 400,859 | |||||
| 2018-02-14 | 13G | XAIR / Beyond Air, Inc. | 500,001 | |||||
| 2018-02-14 | 13G | KKIC / KokiCare, Inc. | 500,001 | |||||
| 2018-02-14 | 13G/A | FATE / Fate Therapeutics, Inc. | 2,615,847 | 0 | ||||
| 2018-02-14 | 13G/A | HRTX / Heron Therapeutics, Inc. | 3,848,161 | 2,179,620 | ||||
| 2018-02-14 | 13G/A | JAGX / Jaguar Health, Inc. | 1,297,815 | 5,462,248 | ||||
| 2018-02-14 | 13G/A | HZNP / Horizon Therapeutics Plc | 12,748,199 | 0 | ||||
| 2018-02-14 | 13G/A | 39036P100 / Great Elm Capital Group, Inc. | 1,269,197 | 1,267,030 | ||||
| 2018-01-02 | 13G/A | AMNL / Applied Minerals, Inc. | 18,587,783 | 18,846,905 | ||||
| 2017-12-21 | 13G/A | AMNL / Applied Minerals, Inc. | 7,052,800 | 18,587,783 | ||||
| 2017-02-17 | 13G/A | AMNL / Applied Minerals, Inc. | 5,572,882 | 7,052,800 | ||||
| 2017-02-15 | 13G/A | 39036P100 / Great Elm Capital Group, Inc. | 1,269,197 | |||||
| 2017-02-15 | 13G/A | 39036P100 / Great Elm Capital Group, Inc. | 1,269,197 | 1,269,197 | ||||
| 2017-02-15 | 13G/A | FATE / Fate Therapeutics, Inc. | 2,596,489 | 2,615,847 | ||||
| 2017-02-15 | 13G | HZNP / Horizon Therapeutics Plc | 4,776,229 | 12,748,199 | ||||
| 2017-02-15 | 13G/A | JAGX / Jaguar Health, Inc. | 1,297,815 | 1,297,815 | ||||
| 2017-02-15 | 13G/A | AMNL / Applied Minerals, Inc. | 5,572,882 | 5,572,882 | ||||
| 2017-02-14 | 13G/A | AMNL / Applied Minerals, Inc. | 6,018,863 | 5,572,882 | ||||
| 2017-02-14 | 13G/A | 39036P100 / Great Elm Capital Group, Inc. | 1,269,197 | |||||
| 2017-02-14 | 13G/A | JAGX / Jaguar Health, Inc. | 734,746 | 1,297,815 | ||||
| 2017-02-14 | 13G/A | PLXP / PLx Pharma Inc. | 975,099 | 0 | ||||
| 2017-02-14 | 13G/A | TNXP / Tonix Pharmaceuticals Holding Corp. | 1,467,858 | 696,455 | ||||
| 2017-02-14 | 13G | HRTX / Heron Therapeutics, Inc. | 1,669,029 | 3,848,161 | ||||
| 2016-02-16 | 13G/A | FLXN / Horizon Funds - Horizon Flexible Income ETF | 769,903 | |||||
| 2016-02-16 | 13G/A | TNXP / Tonix Pharmaceuticals Holding Corp. | 1,467,858 | |||||
| 2016-02-16 | 13G/A | FATE / Fate Therapeutics, Inc. | 2,390,512 | 2,596,489 | ||||
| 2016-02-16 | 13G/A | HZNP / Horizon Therapeutics Plc | 4,776,229 | |||||
| 2016-02-16 | 13G/A | PLXP / PLx Pharma Inc. | 975,099 | |||||
| 2016-02-16 | 13G/A | JAGX / Jaguar Health, Inc. | 726,576 | 734,746 | ||||
| 2016-02-16 | 13G/A | XOMA / XOMA Royalty Corporation | 10,823,779 | 1,012,145 | ||||
| 2016-02-16 | 13G/A | HRTX / Heron Therapeutics, Inc. | 2,833,791 | 1,669,029 | ||||
| 2016-02-16 | 13G/A | AMNL / Applied Minerals, Inc. | 5,739,630 | 6,018,863 | ||||
| 2016-02-16 | 13G/A | VNDA / Vanda Pharmaceuticals Inc. | 934,568 | 934,568 | ||||
| 2015-12-23 | 13G | JAGX / Jaguar Health, Inc. | 726,576 | |||||
| 2015-06-08 | 13G/A | XOMA / XOMA Royalty Corporation | 10,823,779 | |||||
| 2015-06-08 | 13G | HRTX / Heron Therapeutics, Inc. | 2,833,791 | |||||
| 2015-05-28 | 13G/A | FATE / Fate Therapeutics, Inc. | 2,390,512 | |||||
| 2015-05-26 | 13G | AMNL / Applied Minerals, Inc. | 5,739,630 | |||||
| 2015-02-17 | 13G | TNXP / Tonix Pharmaceuticals Holding Corp. | 575,000 | |||||
| 2015-02-17 | 13G | HZNP / Horizon Therapeutics Plc | 6,374,616 | |||||
| 2015-02-17 | 13G/A | VNDA / Vanda Pharmaceuticals Inc. | 2,461,305 | |||||
| 2015-02-17 | 13G/A | AEGR / Aegerion Pharmaceuticals, Inc. | 0 | |||||
| 2015-02-17 | 13G/A | 032420101 / Anacor Pharmaceuticals, Inc. | 1,180,306 | |||||
| 2015-02-17 | 13G | XOMA / XOMA Royalty Corporation | 8,044,676 | |||||
| 2015-02-17 | 13G | FLXN / Horizon Funds - Horizon Flexible Income ETF | 1,037,489 | |||||
| 2015-02-17 | 13G | FATE / Fate Therapeutics, Inc. | 1,554,175 | |||||
| 2015-02-17 | 13G/A | 91531F103 / General Electric Capital Corp. 6.10#% Public Income Bonds PINES due 2032-11-15 | 6,540,246 | |||||
| 2014-11-28 | 13G | PLXP / PLx Pharma Inc. | 730,000 | |||||
| 2014-02-14 | 13G/A | 91531F103 / General Electric Capital Corp. 6.10#% Public Income Bonds PINES due 2032-11-15 | 5,215,346 | |||||
| 2014-02-14 | 13G | AEGR / Aegerion Pharmaceuticals, Inc. | 1,538,410 | |||||
| 2014-02-14 | 13G | VNDA / Vanda Pharmaceuticals Inc. | 2,239,350 | |||||
| 2014-02-14 | 13G/A | 032420101 / Anacor Pharmaceuticals, Inc. | 1,651,437 | |||||
| 2013-07-16 | 13D | 3,640,000 | ||||||
| 2013-02-20 | 13G | 032420101 / Anacor Pharmaceuticals, Inc. | 1,900,000 | |||||
| 2013-02-14 | 13G/A | 91531F103 / General Electric Capital Corp. 6.10#% Public Income Bonds PINES due 2032-11-15 | 4,553,476 | |||||
| 2013-02-14 | 13G/A | 3,640,000 | ||||||
| 2012-02-14 | 13G/A | 39036P100 / Great Elm Capital Group, Inc. | 4,900,001 | |||||
| 2012-02-14 | 13G/A | ACTG / Acacia Research Corporation | 0 | |||||
| 2012-02-14 | 13G/A | OUTR / Outerwall Inc. | 0 | |||||
| 2012-01-26 | 13G | 3,440,000 |
